Eric N. Johnson
Merck & Co.
7 Papers
117 Citations
Eric N. Johnson is an academic researcher from Merck & Co.. The author has contributed to research in topics: Receptor & Benzofuran. The author has an hindex of 6, co-authored 7 publications.
Chat about Author
Papers
Integrating Experimental and Analytic Approaches to Improve Data Quality in Genome-wide RNAi Screens
Xiaohua Douglas Zhang,Amy S. Espeseth,Eric N. Johnson,Jayne Chin,Adam Gates,Lyndon J. Mitnaul,Shane Marine,Jenny Tian,Eric M. Stec,Priya Kunapuli,Dan Holder,Joseph F. Heyse,Berta Strulovici,Marc Ferrer +13 more
TL;DR: This work proposes the implementation of 3 experimental and analytic processes to improve the quality of data from RNAi HTS biotechnology that are likely to have broad utility in genome-wide RNAi research.
42
Discovery of benzofuran propanoic acid GPR120 agonists: From uHTS hit to mechanism-based pharmacodynamic effects.
Matthew Lombardo,Kate Bender,Clare London,Michael A. Plotkin,Melissa Kirkland,Joel Mane,Michele Pachanski,Wayne M. Geissler,John Cummings,Bahanu Habulihaz,Taro E. Akiyama,Jerry Di Salvo,Maria Madeira,Joanna Pols,Mary Ann Powles,Michael F.A. Finley,Eric N. Johnson,Thomas Roussel,Victor N. Uebele,Alejandro Crespo,Dennis Leung,Candice Alleyne,Dorina Trusca,Ying Lei,Andrew D. Howard,Feroze Ujjainwalla,James R. Tata,Christopher Joseph Sinz +27 more
TL;DR: The combination of in vivo efficacy and attractive rodent pharmacodynamic profiles suggests compounds generated from this series may afford attractive candidates for the treatment of Type 2 diabetes.
24
A 1,536-Well [35S]GTPγS Scintillation Proximity Binding Assay for Ultra-High-Throughput Screening of an Orphan Gαi-Coupled GPCR
TL;DR: Members of the superfamily of seven transmembrane receptors, known as G protein-coupled receptors (GPCRs), are important targets for many therapeutic areas in drug discovery.
23
Iterative Focused Screening with Biological Fingerprints Identifies Selective Asc-1 Inhibitors Distinct from Traditional High Throughput Screening.
Peter S. Kutchukian,Lee Warren,Brian C. Magliaro,Adam Amoss,Jason Cassaday,Gregory O'Donnell,Brian Squadroni,Paul Zuck,Danette Pascarella,J. Chris Culberson,Andrew J. Cooke,Danielle M. Hurzy,Kelly-Ann S. Schlegel,Fiona Thomson,Eric N. Johnson,Victor N. Uebele,Jeffrey D. Hermes,Sophie Parmentier-Batteur,Michael F.A. Finley +18 more
TL;DR: To identify novel Asc-1 inhibitors, two different screening approaches were performed with whole-cell amino acid uptake in heterologous cells stably expressing human Asc- 1, and the implementation of counter screens to remove nonspecific inhibitors of radioactive amino acids uptake was implemented.
A combination of ultrahigh throughput PathHunter and cytokine secretion assays to identify glucocorticoid receptor agonists.
TL;DR: The data indicate that using the PathHunter assay, compounds that showed agonism for the GR receptor in primary human monocytes and due to their performance in a physiologically relevant model they likely will have a better chance to evoke clinical efficacy.
19